Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
exelon | New Drug Application | 2024-05-08 |
rivastigmine | ANDA | 2024-09-21 |
rivastigmine tartrate | ANDA | 2024-10-24 |
rivastigmine transdermal system | ANDA | 2025-01-15 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
alzheimer disease | EFO_0000249 | D000544 | F03 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
Drug common name | Rivastigmine |
INN | rivastigmine |
Description | Rivastigmine is a carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor, a neuroprotective agent and a cholinergic drug. It is a carbamate ester and a tertiary amino compound. It is a conjugate base of a rivastigmine(1+). |
Classification | Small molecule |
Drug class | cholinesterase inhibitors (physostigmine type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1 |
PDB | — |
CAS-ID | 123441-03-2 |
RxCUI | — |
ChEMBL ID | CHEMBL636 |
ChEBI ID | 8874 |
PubChem CID | 77991 |
DrugBank | DB00989 |
UNII ID | PKI06M3IW0 (ChemIDplus, GSRS) |